2013
DOI: 10.1177/1087057112462131
|View full text |Cite
|
Sign up to set email alerts
|

Identification and Characterization of Novel Human Glucose-6-Phosphate Dehydrogenase Inhibitors

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
43
0

Year Published

2014
2014
2024
2024

Publication Types

Select...
5
2
1

Relationship

0
8

Authors

Journals

citations
Cited by 53 publications
(43 citation statements)
references
References 29 publications
(56 reference statements)
0
43
0
Order By: Relevance
“…37 These inhibitors, however, have a low efficacy (IC 50 40.4 and 3 mmol/L, respectively) and limited solubility in ACSF, factors that made the use of 6-aminonicotinamide impossible in our experiments. Conversely, dehydroepiandrosterone at 0.3 mmol/L concentration induced strong hyperexcitability manifested by drastic increase in field responses and emergence of interictal spontaneous activity (Supplementary Figure S2), effects that may be explained by its multi-faceted and unspecific activity (e.g., inhibition of GABA A receptors 38 or increase in spontaneous glutamate release 39 ).…”
Section: Replacement Of Glucose With Mitochondrial Energy Substrates mentioning
confidence: 97%
“…37 These inhibitors, however, have a low efficacy (IC 50 40.4 and 3 mmol/L, respectively) and limited solubility in ACSF, factors that made the use of 6-aminonicotinamide impossible in our experiments. Conversely, dehydroepiandrosterone at 0.3 mmol/L concentration induced strong hyperexcitability manifested by drastic increase in field responses and emergence of interictal spontaneous activity (Supplementary Figure S2), effects that may be explained by its multi-faceted and unspecific activity (e.g., inhibition of GABA A receptors 38 or increase in spontaneous glutamate release 39 ).…”
Section: Replacement Of Glucose With Mitochondrial Energy Substrates mentioning
confidence: 97%
“…The results achieved are shown in table 2. shown that this key metabolic enzyme which catalyzes the first step of pentose phosphate pathway is expressed abundantly and very active in human tumors [21]. In contrast, G6PD-deficient tumor cell lines showed relatively slow growth and enhanced apoptosis [41].…”
Section: Resultsmentioning
confidence: 99%
“…G6PD activity increases in cancer cells and its inhibition results in decrease of cell proliferation and induction of apoptosis. For example, 6-aminonicotinamide which is an inhibitor of G6PD has found use in the therapy of various tumors in the past [21].…”
Section: Introductionmentioning
confidence: 99%
“…Recently, novel inhibitors of the human G6PDH 23 and of the bifunctional glucose-6-phosphate dehydrogenase 6-phosphogluconolactonase from Plasmodium falciparum (PfGluPho) 24 were identified by HTS. However, no uncompetitive inhibitors were reported from those experiments.…”
Section: Resultsmentioning
confidence: 99%
“…1A). [23][24][25][26][27] The primary screening assay resulted in the identification of 96 hit candidates, which diminished the enzyme activity to at least 62.5%, which is equivalent to the mean percentage of enzyme activity less 5 standard deviations (Fig. 1B).…”
Section: Primary Screeningmentioning
confidence: 99%